Novel Strategies to Improve Rituximab Efficacy in Non-Hodgkin's Lymphomas
Open Access
- 10 March 2015
- journal article
- Published by Peertechz Publications Private Limited in Global Journal of Cancer Therapy
- Vol. 1 (1), 005-006
- https://doi.org/10.17352/gjct.000002
Abstract
Global Journal of Cancer Therapy is an academic, open access and well-established journal which is keen to publishing high quality manuscripts focusing on cancer therapy. The peer reviewed journal which creates scientific platform is taking into an account on all the most recent and outstanding research articles, technical reports, regular book reviews, scientific data, letters, opinions, reviews, editorials, case reports and short communication in all major areas of Cancer therapy.Keywords
This publication has 8 references indexed in Scilit:
- Rituximab and Other New Anti-CD20 MAbs for Non-Hodgkin’s Lymphoma TreatmentEMJ Oncology, 2014
- Treatment challenges in the management of relapsed or refractory non-Hodgkin’s lymphoma – novel and emerging therapiesCancer Management and Research, 2013
- mAbs targeting CD20 and other lymphocyte CD markers in lymphoma treatmentPublished by Future Medicine Ltd ,2013
- Novel antibodies against follicular non-Hodgkin’s lymphomaBest Practice & Research Clinical Haematology, 2011
- Rituximab resistanceBest Practice & Research Clinical Haematology, 2011
- Rituximab: Mechanism of ActionSeminars in Hematology, 2010
- Monoclonal Antibodies for B-Cell Lymphomas: Rituximab and BeyondHematology, 2007
- The conjugate Rituximab/saporin-S6 completely inhibits clonogenic growth of CD20-expressing cells and produces a synergistic toxic effect with FludarabineLeukemia, 2004